Diag-Nose.io

Executive Summary

Diag-Nose.io is a precision respiratory medicine company leveraging its proprietary RhinoMAP platform to transform respiratory care from symptom-based to biomarker-driven diagnostics and therapeutics. By combining nasal microsampling, proteomics, and machine learning, RhinoMAP decodes individual airway biology, enabling early detection, patient stratification, and targeted therapy development. The company addresses the $40B respiratory diagnostics market, with initial focus on asthma and COPD, where misdiagnosis and suboptimal treatment are common. Its non-invasive sampling and AI-powered analytics offer a scalable solution for both clinical trials and routine care, potentially reducing time-to-diagnosis and improving patient outcomes. Founded in 1990 and headquartered in San Francisco, Diag-Nose.io has a long track record in respiratory research but is now pivoting to commercialize its precision medicine platform. While the company remains private with limited public disclosures, its technology aligns with the growing demand for personalized medicine and digital health integration. The primary risk lies in clinical validation and regulatory clearance, as well as competition from established diagnostics players and emerging liquid biopsy companies. However, the unique combination of nasal microsampling and proteomics positions Diag-Nose.io as a potential leader in the unified airway approach, bridging the gap between allergy, asthma, and COPD management. The company's ability to secure partnerships with pharmaceutical firms and navigate FDA pathways will be critical to its near-term success. Overall, Diag-Nose.io represents a compelling opportunity in the precision diagnostics space, though execution risks temper near-term conviction.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal clinical study for RhinoMAP in asthma exacerbation prediction65% success
• Q3 2026Strategic partnership with top-20 pharma for biomarker discovery in COPD55% success
• Q2 2026Series B funding round to support commercial launch and FDA submission70% success